Tipranavir (Aptivus)

Overview | News | Research

Overview

Prescribing Information for Tipranavir (Aptivus) (PDF) (April 2011)
From Boehringer Ingelheim
Tipranavir: The First Nonpeptidic Protease Inhibitor (Winter 2003/2004)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation

News

New Pediatric Dosing for Aptivus, Patients 2-18 Years, New Oral Solution and Info on Coadministration With Midazolam (June 23, 2008)
From U.S. Food and Drug Administration
U.S. FDA Approves New Anti-HIV Drug Aptivus for Use in Combination Therapy (June 23, 2005)
From Boehringer Ingelheim
FDA Approval of Aptivus (Tipranavir) (June 23, 2005)
From U.S. Food and Drug Administration
Tipranavir (Aptivus): Approval Cautiously Recommended (June 20, 2005)
In AIDS Treatment News, from AIDS Treatment News
Tipranavir Patients May Experience Intracranial Hemorrhage, FDA Warns (June 30, 2006)
From U.S. Food and Drug Administration

Research

Clinical Trials Using Tipranavir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Novel Mutations and Shifting Susceptibility to Darunavir and Tipranavir (September 15, 2010)
From National AIDS Treatment Advocacy Project
New Data on Tipranavir Highlight the Agent's Benefits (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
A Research Update on Tipranavir (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
A Thorough Look at Tipranavir Based on Studies Assessing Its Efficacy, Resistance and Safety (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Ritonavir-Boosted Tipranavir More Effective Than Other Ritonavir-Boosted PIs in HIV-Infected Patients With PI Resistance (August 17, 2006)
In XVI International AIDS Conference
Use of Tipranavir for Patients With Little Prior PI Experience (August 15, 2006)
In XVI International AIDS Conference

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	CROI 2013: Research on Aging and HIV (Video)
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.